Compare Cytokinetics Inc (CYTK) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Ross Stores, Inc. — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Ross Stores, Inc. trades at $221.99 (market cap $70.87B). The key difference: Ross Stores, Inc. is far larger — about 6.4× Cytokinetics Inc's market cap, and Ross Stores, Inc. pays a 0.81% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | ROST | |
|---|---|---|
Market Cap | $11.12B | $70.87B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $240.13 |
52-Week Low | $33.23 | $127.59 |
Enterprise Value | $11.59B | $71.46B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Ross Stores (ROST) trades at $219.46, down 1.53% on the day, with a bullish technical outlook supported by moving averages and consistent earnings beats. The company demonstrates strong profitability with a 9.74% net margin and 38.98% ROE, while revenue grew to $21.13B in 2025. Recent news highlights robust Q1 2026 performance with 21% sales growth and expanding margins.
The stock offers upside to the $259 consensus price target, driven by operational efficiency and store expansion. Risks include consumer spending sensitivity and competitive pressures. Analyst sentiment is strongly positive with 64% buy ratings, though valuation multiples like the 30.65 P/E warrant monitoring amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
